NCT06039566 NAC vs Placebo on Opioid Use for Hysterectomy
| NCT ID | NCT06039566 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Medical University of South Carolina |
| Condition | Hysterectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-11-30 |
| Primary Completion | 2026-11-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 240 participants in total. It began in 2023-11-30 with a primary completion date of 2026-11-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will enroll females who are ages 18 and older undergoing a laparoscopic or robotic, partial or full hysterectomy. Participants will be randomized to receive IV n-acetylcysteine or placebo during the first 60 minutes of their procedure. At various time points after the procedure patients will be asked to report their pain scores, and any pain medication taken.
Eligibility Criteria
Inclusion * Undergoing elective laparoscopic or robotic, full, or partial hysterectomy procedure * 18 years of age and older Exclusion * Less than 40kg in weight * Unable to provide written, informed consent * History of an adverse or anaphylactoid reaction to acetylcysteine * Active asthma, wheezing, or using inhaled bronchodilators * Non-English speaking * Insulin dependent diabetes if D5W is required * Blood clotting disorders
Contact & Investigator
Sylvia Wilson, M.D.
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT06039566 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hysterectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06039566 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 240 participants.
Is NCT06039566 currently recruiting?
Yes, NCT06039566 is actively recruiting participants. Contact the research team at nitchie@musc.edu for enrollment information.
Where is the NCT06039566 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT06039566 clinical trial?
NCT06039566 is sponsored by Medical University of South Carolina. The principal investigator is Sylvia Wilson, M.D. at Medical University of South Carolina. The trial plans to enroll 240 participants.